Logo1
ASTS - 2012 American Transplant Congress - Nurses, Pharmacists OR Others
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
Please rate the following:
The program was relevant to my work.
Content matched stated objectives.
Usefulness of handouts/AV.
Quality of facilities.
How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?
If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Objective 1: Discuss up-to-date information on transplant research, surgical techniques, patient management, social, ethical, and political issues in the transplantation community.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
Objective 2: Recognize and understand the challenges facing the clinical care of solid organ and tissue transplantation, including potential strategies to optimize patient outcomes.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Objective 3: Evaluate current treatment and disease prevention strategies for transplant recipients.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Discuss major provisions impacting high cost areas such as transplantation.
Discuss the legal challenges to health reform and possible outcomes of the Supreme Court involvment.
Discuss the difference between allowable and reimbursable costs.
Identify cost and revenue areas within their transplant program that need to be optimized.
Summarize the potential impact of health reform on their transplant porgram(s).
Cite various forms of immune regulation.
Describe how viruses and vaccines may affect allo-immunity.
Discuss strengths, weaknesses and future applications of transcriptomics.
Discuss components of immunosuppressive regimens thought to promote tolerance.
Review and evaluate the latest clinical and basic science advances in Immunogenetics and Histocompatibility.
List the key molecular regulators of apoptotic and necrotic programmed cell death pathways.
Discuss mechanisms that allow the innate immune system to detect sterile tissue injury.
Identify pre transplant and post transplant considerations with native liver malignancy and management of immunosuppression.
Discuss immunosuppression management post transplant in patients with de novo non hepatic malignacy including PTLD.
Discuss the impact of immunosuppression on HIV progression following transplantation.
Discuss the pharmacokinetic interactions between immunosuppression and antiviral agents.
Review and evaluate the latest clinical and basic science advances in Immunogenetics and Histocompatibility.
Discuss how to address the challenges that we face in this regulated environment.
Discuss when a program application is obligated to be submitted by OPTN requirements.
Explain how to integrate QAPI into daily operations to drive improvement, maintain improvements or compliance and to be sensitive to early warning signs of problems.
Discuss where to find personnel requirements for transplant program personnel.
Discuss basic mechanisms that lead to transplant allograft injury.
Identify strategies used by epithelial cells to limit injury during inflammation.
Cite potential therapeutic strategies of allograft fibrosis.
Discuss potential biomarkers of allograft failure.
Discuss the consequence of inflammatory and dammage-mediated signals on alloimmunity.
Describe activation of innate immune system leading to cell injury and death.
Describe fundamental role of TAM signaling in immune regulation and inhibition.
Discuss the relevance of autophagy to human diseases.
Identify pre transplant and post transplant considerations with native liver malignancy and management of immunosuppression.
Discuss immunosuppression management post transplant in patients with de novo non hepatic malignacy including PTLD.
Discuss the impact of immunosuppression on HIV progression following transplantation.
Describe the pharmacokinetic interactions between immunosuppression and antiviral agents.
Identify available tools and strategies for managing polypharmacy in the transplant receipient.
Evaluate the concept of HLA epitopes.
Discuss the CMS process for transplant centers to apply for mitigating factors (MF) in cases where recent patient or graft survival has not been within Medicare tolerance limits.
List key elements of QAPI systems and some common problems identified through CMS reviews.
Review the interactions between OPTN/UNOS policies and CMS COP.
Describe what CMS does with identified deficiencies.
Discuss the evidence for immune regulation in humans.
Describe how viruses and vaccines may affect allo-immunity.
Discuss the role of immunological monitoring in infectious diseases post-transplant.
List methods to analyze transcriptome expression and profiles.
Discuss differences in the approach to and markers of tolerance in kidney and liver transplant recipients.
Examine the critical issues related to Immunogentics and Histocompatibility testing in transplantation.
Discuss indications as well as inclusion/exclusion for transplantation as well as other treatment options for patients with hilar cholangiocarcinoma.
Discuss UNOS criteria for HCC exceptions treatment options to keep patients within criteria waiting list dynamics.
Explain the rationale and objectives of down-staging of hepatocellular carcinoma.
List key elements for managing osteoporosis post-transplant.
Identify strategies for managemment of metobolic syndrome after transplantation.
Identify transition practices and resources currently used at transplant centers.
Decribe the current state of living kidney donor follow up and areas of unmet need.
Discuss considerations that underlie delivery of wellness to the kidney donor in a clinical setting.
List mechanisms that contribute to the development of tolerance.
Identify barriers to achieving tolerance.
Describe assays or biomarkers that may be associated with tolerance.
Categorize vascularized composite allograft skin rejection.
Describe the defining features to diagnose acute rejection in a vascularized composite allograft.
Discuss various approaches and strategies for tolerance induction for VCA.
Define the role of immune responses in acceptance of VCA.
Discuss new therapies for BOS.
Briefly discuss potential future treatments for BOS.
Define primary graft dysfunction, it's prognosis and pathophysiology.
Examine the broad but critical issues in transplantation, including social and policy issues.
Discuss new data on risks and treatments for known infections in lung transplant recipients.
Describe modifications in renal function after liver transplantation.
Define the role of alternate immunosuppression strategies in changing renal function.
Discuss how to minnimize immunosuppression and prevent side effects.
Define the role of patient using a drug that requires REMS.
Identify the immunosuppressants that currently have FDA approved REMS.
Discuss the application of REMS in organ transplantation.
Discuss the effects of the commensal flora on Treg differentiation.
Discuss peripheral development of regulatory T cells in response to commensal bacteria.
Describe possible treatment modalities in manipulating intestinal microflora.
Identify the primary pathways by which IgG antibodies trigger inflammation.
Explain the roles of canonical Fc receptors in the immune response.
Describe how intravenous gamma globulin suppresses inflammation through novel Fc receptors.
Review clinical and basic advances in predicting severity of HCV recurrence following liver transplantation.
Discuss the new classes of directly acting antiviral therapy for hepatitis C.
Define predictors of severity of HCV recurrence.
Discuss new antiviral therapies in liver transplant setting, management issues, preliminary outcomes.
Discuss the concept of IFN-free regimens and the potential benefits and limitations.
Discuss the preliminary results of the ALTOLD study.
Discuss current knowledge gaps in the field of living kidney donation.
List strategies to maximize scientific productivity from living donor research.
Explain the role that damage to the microcirculation of solid organ transplants may have in the evolution of chronic rejection.
Discuss the historical aspects of organ transplantation in America.
Define the role of the bronchial microvasculature in lung allograft health and disease.
Identify potential markers of injury to the bronchial circulation
Discuss key elements of the psychosocial evaluation process for hand or face transplant.
Discuss the treatment and prevention of infection with VCA.
Discuss the immuno-modulatory protocol using donor marrow infusion and FK-506 monotherapy.
Describe how viruses and vaccines may affect allo-immunity.
Discuss which influenza vaccines are indicated for transplant recipients.
Discuss the details of the controversy of vaccination and rejection.
Define the role of immunological monitoring in infectious diseases post-transplant.
Discuss the more recently advances in "omics" and its application to the transplant field in biomarker.
Define key requirements for a new biomarker to be clinically useful.
Discuss how nHLA antibodies can correlate with acute and chronic graft injury.
Outline the risks of cancer after transplantation.
Discuss therapeutic options for transplant patients with cancer.
Explain how DTAC analyzes potential donor tumor transmissions and of recent modification to that approach.
Describe the impact of intra-patient and inter-patient variability on calcineurin inhibitor therapy.
Discuss the issues associated with generic drug subsitution of the immunosuppressants in organ.
Utilize drug concentration measurements in routine clinical practice.
Identify tools available for monitoring a pharmacodynamic biomarker to optimize.
Discuss efficacy and side effects of anti-HCV therapy.
Describe how to manage the liver transplant recipient with HCV before and after transplantation.
Discuss what  the retrospective data tells us about how patients become highly sensitized.
Discuss the benefits and risks of transplant nephrectomy after a failed transplant.
Discuss the use of KDIGO guidelines for managing the patient with a failing transplant.
Discuss the difference between virtual and physical crossmatches.
Define the differences between PRA and cPRA.
Discuss the scope of use of the VXM in organ allocation.
Describe the relationship between VXM and actual XM using currently available technologies.
Review and evaluate the latest clinical and basic science advances in transplantation science, medicine and surgery.
Examine the broad but critical issues in transplantation, including social and policy issues.
Discuss the need for improved lung preservation.
Discuss the benefits and pitfalls of EVLP.
Describe the impact of DGF on transplant center expenditures.
Assess the long term impact of DGF on spending for renal replacement therapy.
State possible definitions of delayed graft function after kidney transplantation.
Explain the challenge of selecting appropriate endpoints and designing clinical trials to reduce or mitigate DGF.
Discuss adverse consequences of delayed graft function.
Explain the role of carbon monoxide in reducing the severity of delayed graft function.
Discuss the rationale for traditional 3 drug immunosupression.
Discuss trial data regarding minimized immunosuppression.
Describe the mechanisms of standard and new immunosuppressive agents.
Review and evaluate the latest clinical and basic science advances in cardiac allograft rejection.
Assess the impact of alemtuzumab on outcomes after cardiac transplantation.
Describe the role of liver transplant for ALF.
Discuss the importance of circulation to maintain organ function.
Describe the effect of existing organ dysfunction on overall outcome.
Distinguish between acute liver failure (ALF) and acute decompensation of chronic liver disease (ACLF).
Discuss the implications for post-transplant outcome for patients transplanted from the ICU.
Discuss how to prevent Intestinal failure.
List the major causes of death and graft loss in the long term after intestine transplantation.
Review possible strategies to overcome late graft loss or morbidity/mortality.
Discuss how to differentiate hypotheses from experimental results.
Utilize schematic illustrations to communicate testable working models.
Discuss grant writing techniques.
Explain how to avoid common grant errors.
Discuss the consequence of inflammatory and dammage-mediated signals on alloimmunity.
Identify the five principles of clear scientific writing.
Apply these principles to one's own scientific writing, particularly with regard to manuscripts.
Discuss the indications for pancreas transplant.
List the diagnostic criteria for pancreas allograft dysfunction.
Discuss the main differential diagnosis of severe AMR leading to early graft loss.
Describe the rationale for gaining a better understanding of diagnosis and treatment of pancreas allograft AMR.
Define the components for the diagnosis of acute antibody-mediated rejection of the pancreas allograft.
Discuss the current proposed guidelines for reducing the transmission of HIV, HCV or HBV via solid organ transplantation.
Discuss epidemiologic factors in donors at increased risk for HIV, HBV, and HCV transmission to recipients.
Describe the importance to test recipients who receive organs from donors at increased risk for HIV, HBV, and HCV infection.
Discuss how to monitor for HCC recurrence (biomarkers, imaging), data on different immunosuppression strategies to prevent recurrence.
Recognize current limitations of molecular markers.
Discuss latest developments in reserach for biomarkers for hepatocellular carcinoma.
List prognostic factors for hepatocellular carcinoma in the transplant setting.
Discuss mechanisms of fibrosis and microvascular rarefaction in chronic allograft disease.
Discuss principles of fibrosis diagnosis.
Discuss novel pathways of allograft fibrosis.
Discuss the importance of innate immunity in early graft injury.
Identify trends regarding patient involvment as active partners in their care.
Discuss the benefits of remote data sharing and communicating between transplant patients and clinicians as a means of sharing responsibility for clinical management in the setting of transplantation.
Discuss the importance of assessing perceived barriers to adolescent medication adherence.
Explain how virtual communities increase the social support network for patients around adherence challenges and assist in problem solving to improve adherence.
Describe the genetic basis of transplantation tolerance.
Discuss the role of inflammation and organ transplantation Infections and Transplantation.
Describe how unspecific injuries, including brain death, IRI and senescence impact the immunogenicity of organ grafts.
Explain how donor and recipient age impact allorecognition, alloimmunity, and tolerance.
Review the molecular definitions of T cell mediated and antibody-mediated rejection.
Review the molecular definition of acute organ injury.
Illustrate the opportunities for molecular diagnostics will change patient management.
Discuss advances in molecular diagnostics.
Identify factors that typically result in regulation, where regulation adds net value, where regulation risks creating negative net value.
Identify trade-offs involved in regulation, and some of the markers worth watching.
Define the role of CMS in regulation.
Discuss potential side effects of regulation.
Discuss how stem cells are generated by reprogramming skin and blood samples from patients.
Explain how novel pluripotent stem cell populations may be clinically applied to help patients.
Identify barriers to clinical application of bridge to transplant liver xenografts.
Discuss current state of genetically engineered pigs for liver xenotransplantation.
Discuss the pathogenesis of viral diseases posttransplant.
Identify patients at high risk for viral disease posttransplant.
Discuss the benefits of prophylaxis versus preemptive therapy.
Discuss risk and management of ganciclovir resistance and use of maintenance therapy.
Discuss the state of the art of HLA antibody testing.
Discuss the utility of cPRA and virtual crossmatching.
Discuss the limitations of virtual crossmatch relative to the actual crossmatch.
Discuss recent technical advances in living donor nephrectomy with emphasis on single port donor nephrectomy.
Discuss patient outcome data with regards to outcomes, complications, and satisfaction that may encourage living kidney donation with application of single port technique.
Identify barriers to initiating a single incision laparoscopic donor nephrectomy program.
Compare donor and recipient outcomes of standard laparoscopic and single incision laparoscopic donor nephrectomy.
Discuss the use of marginal donors.
Determine which marginal donors fit with each recipient.
Discuss the risks of marginal donors.
Define and describe the various assays for detecting circulating antibodies in patients awaiting heart transplantation.
Identify and appropriately apply strategies to reduce circulating antibodies in patients awaiting heart transplantation.
Identify appropriate monitoring of sensitization patients after heart transplantation.
Cite the clinically relevant alloantibodies.
Discuss the SRTR data request process.
List some key issues around data quality.
Explain how to convert SAS files to other formats, the structure of the Standard Analysis File, and how to appropriately link files.
Discuss psychosocial barriers to organ donation & transplantation among Hispanics/Latinos.
Describe the steps taken in order to develop a program specially oriented for the Latino community.
Describe the 2-dimensional model of cultural sensitivity (Resnicow et al. 1999) and its relevance to donation/transplant-related interventions targeting Hispanics.
Discuss using using microRNAs as biomarkers.
Analyze the mechanism of organ damage due to ischemia/treperfusion injury in transplant recipients.
Review principles of purinergic signaling and regulation.
Discuss relevance to basic science, theory and clinical practice of the properties of protective genes e.g. CD39.
Explore the expansion of transplant tourism around the world.
Explore how transplant tourism strips altruism away from the donor-recipient relationship.
Examine why patients seek transplantation outside of the United States.
Discuss what regulations are in place or being considered to curtail transplant tourism.
Describe major gaps in knowledge for immunosuppression
Identify possible solutions for immunosuppression-related questions in kidney transplantation
Describe the documented risks of belatacept
Identify kidney transplant recipients suitable for a trial of steroid-free immunosuppression regimen
Discuss limitations in current immunosuppressive agents
List 3 risks that threaten transplant and survival in the elderly
Compare transplant versus dialysis in the elderly
Discuss current outcomes of transplant patients with increased bmi's
Describe methods in which programs can evaluate the impact of non-codifed factors on their performance
Discuss common reasons for which patients are currently delisted
Discuss the requirement and dependence of success on a dual structure of leadership between
Utilize proven management principles in a novel setting improve outcomes at all levels of the organization
Discuss the means to acquire resources to support program activities and strategies to review program performance prospectively to avoid being flagued by UNOS and CMS
Discuss the data on outcome for elderly transplant patients
Evaluate the risks and benefits in elderly transplant patients
Describe the necessary components of the transplant re-evaluation
Identify information to use with wait list population
Discuss cardiac prognosis in patients with CAD
Discuss the benefits and distractions of being a transplant physician
Discuss the CMS perspective with respect to the evaluation of transplant center quality
Evaluate the association of SRTR performance evaluations and center kidney volume
Describe the relationship between deceased donor risk and SRTR performance evaluations
Discuss lymph node anatomy
Describe DC priming of T cells in vivo
Discuss the concept of intravital microscopy
Discuss the concept of directing cells
Describe how  immunology affects cells in rejection
Define which cells play a role in rejection
Explain the role of specific cells in rejection
Discuss the benefits and pitfalls of EVLP.
Discuss the pathophysiology of Type I Diabetes Mellitus
Discuss isolated islet transplantation
Discuss risks and benefits of specific immunizations in the transplant recipient
Describe management and counseling with respect to particular environmental infectious exposures of concern
Discuss determinants of hypertension in transplant recipients
Discuss the importance of cancer as a cause of morbidity and mortality in transplant recipients
Discuss signaling pathways that affect regulatory T cell function
Explain how the in vitro inhibition of one of these pathways, the GSK-3beta pathway, affect regulatory T cell function
Describe how the in vivo inhibition of the GSK-3beta pathway affect islet allotranspant survival
Discuss new data indicating a role for CDK in peripheral T cell tolerance
Discuss basic aspects of cytokine signaling and the roles of Jaks and Stats
Discuss psychiatric morbidity following donation
Explain decision making algorithm while evaluating acute liver failure patients in a timely fashion
Summarize key elements of Psychosocial evaluation in fulminant liver patients
Describe ethical considerations in fulminant liver failure patients
Describe the prognosis of patients with substance dependence in terms of relapse risk
Discuss the impact of substance abuse upon treatment adherence post transplant
Discuss the policies that regulate the UNOS Kidney Paired Donation System
Describe how to optimize your computer matching procedure
Discuss the experiences and difficulties encountered during implementing national network of kidney paied donation in Korea
Identify challenges faced by a transplant center participating in a kidney exchange program
List strategies to address the challenges of paired exchange donation
Discuss future directions of Kidney Paired Donation
Identify grant writing techniques
Explain how to avoid common grant errors
Discuss the limitations of HLA antibody testing
Outline diagnostic modalities for AMR
Discuss the benefits and distractions of being a transplant physician
Discuss the pathologic and immunologic criteria for the diagnosis of antibody-mediated rejection in heart transplantation
Describe therapeutic options for AMR
Discuss the phenotypic differences between cellular and AMR
Describe clinical strategies for the management of AMR
Illustrate immunofluorescence features of antibody mediated rejection in heart allografts
Discuss the use of IgG and C1q assays for monitoring desensitization.
Discuss the importance of myeloid cells and their subsets in inflammation
Define the role of Kruppel-like Factors in myeloid cell biology
Discuss how macrophages and other immunoregulatory myeloid antigen presenting cells (APC) are emerging as potent modulators of alloreactive T cells
Identify major types of regulatory cells that effect regulation
Discuss the functional activity of Treg in auto and alloresponses
Discuss the relative contributions of thymic and peripheral mechanisms to immune tolerance
Identify different subsets of myeloid derived suppressor cells that accumulate in transplant allografts
Discuss the development of myeloid derived suppressor cells
Review current state of the field of regulatory T cell biology
Identify barriers/challenges to transition from a pediatric practitioner's perspective
Identify strategies for assessing transition readiness
Discuss current models of adolescent-to-adult care in solid organ transplantation
Compare and contrast current outcomes of adolescent transplant versus other
Identify current tools used to measure successful transition of care from the pediatric to adult transplant center and areas of potential study.
List the HIV medications that are most problematic with regards to drug interactions with immunosuppressants
Discuss the necessary dosage adjustments needed post transplant in HIV and immunosuppressive medications
Identify patients at high risk for viral disease posttransplant
Identify gaps in therapies for fungal infection in transplantation
Recognize the limitations and gaps in the development of field of transition
Describe current use of technology by adolescents
Discuss current eHealth and mHealth transition initiatives
Outline how to tailor a successful transition process to meet local needs and resources
Describe how to develop a centre-specific transition "toolkit"
Explain the importance of myeloid cells and their subsets in inflammation
Define the role of transcription in physiology and pathology
Discuss the assays available to study non-HLA antibodies and apply this informatino to improve patient diagnostics and care
List new techniques for Biomarker discovery
Articulate the options that are available in the field of incompatible transplantation
Evaluate new therapies for desensitization and incompatible transplantation
Discuss the mechanism of eculizumab and its role in desensitization
Identify examples of eculizumad related to desensitization
Discuss the mechanisms of antibody production
Discuss the mechanism of action of rapamycin
Discuss the ability of mTOR inhibition to promote the generation of Regulatory T cells
Define the role of mTOR in CD8T cell mediated immunity
Discuss therapeutic modalities to alter effector and memory differentiation
Discuss the perioperative management of hepatorenal syndrome during liver transplantation
Review the different challenges for biomarker discovery and implementation in transplantation
Discuss the causes of post-transplant renal disease
Identify some strategies to reduce post-transplant renal disease
Discuss the results of the clinical evaluation of tofacitinib in kidney transplant recipients
Identify the risks and potential benefits associated with the new immunosuppressive drug tofacitinib
Discuss the latest, potential new agents for transplantation
Discuss the target population and potential use
Discuss adverse events associated with costimulation blockade
Identify those patients most likely to benefit from using Everolimus immunosuppression
Apply new diagnostic algorithms for differentiating between recurrent hepatitis and rejection in liver allografts
List new molecular tools for predicting immunological accommodation in liver transplant patients
Discuss the need for long term immunosuppression in liver transplantation
Define the components of tertiary lymphoid organs (TLO)
Discuss data relative to TLO formation in human transplants
Discuss the distinction between secondary and tertiary lymphoid organs
Explain the function of tertiary lymphoid organs
Discuss the role of FDA Clinical Pharmacology in immunosuppressant drug / biologics development
Identify key considerations for Fixed Dosing vs. Therapeutic Drug Monitoring of immunosuppressant drugs / biologics
Discuss the history of the Orphan Drug Act
Recognize when a non-inferiority transplantation trial is needed over a superiority trial
Identify where to seek public information useful for investigators and healthcare providers
Recognize transplant bone disease and rule out other causes
Discuss when to refer for further evaluation by bone metabolism expert
Define health literacy and its importance for organ transplant patients
Describe how limited health literacy can adversely affect transplant patients' health outcomes
List the 3 different types of pain that a transplant patient may experience
Explain how chronic pain management includes managing physical and emotional pain
Discuss the brain being an immuno-priviledged organ
Define the role of mesenchymal stromal/stem cells in cell and organ transplantation
Discuss immunoregulation of human T cells by genetically modified mesenchymal stromal cells
Discuss xenotranplantation from GalKO or transgenic pigs
List desirable characteristics of immunosuppression for islet transplantation
Discuss the current status of clinical islet transplantation
State the limitations of islet replacement therapy and discuss steps being applied to address these limitations
Define the next steps that will take islet transplantation into routine clinical care
Discuss the differential diagnostic challenges in cases with post transplant infectious diseases
Review the pathogenesis of BKV interstitial nephritis
Compare differences in mechanisms of action for various immunosuppressants and antiviral agents in the suppression of rejection and BKV reactivation
Discuss surrogate markers used to assess abnormal states in allografts
Define the differences between PRA and cPRA Understand the limitations of solid phase testing
Explain the relevance and limitations of isohemagglutinin titre testing
Discern possible differences in accommodation vs rejection of ABO-incompatible heart grafts
Discuss the relevance and limitations of isohemagglutinin titre testing
Discuss the framework of transplant center design
Describe the benefits of institutional participation in clinical trials
Explain the ways finance affects clinical trials
Identify ways to maximize revenue account to augment transplant center stability and financial independence
Discuss new avenues for research in basic and translational science
Discuss new issues with regards to allocation
Cite new surgical and medical issues with regards to transplant
Manage antiviral therapy in the pre- and post-transplant setting
Advise HCV patients regarding outcomes from current and future treatments
Define appropriate post liver transplant care of patients who had hepatitis B pre liver transplant
Discuss donor evaluation and utilization of donors exposed to HBV and HCV
Objective 4: Recognize current practices, emerging technologies and medical advances related to organ allocation, procurement, preservation and ex-vivo treatment, and their implications for organ viability and recipient outcomes.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Please answer the following:
Do you believe this activity was appropriate for the scope of your professional activities?
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
How much did you learn as a result of this education program?
What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?
What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments:

Mr question